We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Global Contrast Enhanced Ultrasound Market Driven by Demand for Early Detection of Chronic Diseases

By MedImaging International staff writers
Posted on 22 Aug 2023
Print article
Image: The contrast enhanced ultrasound market is estimated to surpass USD 2 billion by 2028 (Photo courtesy of Freepik)
Image: The contrast enhanced ultrasound market is estimated to surpass USD 2 billion by 2028 (Photo courtesy of Freepik)

Contrast-Enhanced Ultrasound (CEUS) is a non-ionizing imaging method that differs from CT scans and X-rays in its non-utilization of ionizing radiation. This inherent feature results in minimal patient risk, rendering it a safer alternative, particularly for vulnerable groups such as pregnant women, children, and those with delicate health conditions. CEUS employs contrast agents to enhance the visualization of blood flow and perfusion within bodily organs and tissues. This heightened precision in imaging soft tissues renders CEUS especially valuable for the assessment of vascular irregularities, detection of minute lesions, and characterization of tumors. CEUS stands out for its ability to provide real-time, dynamic imagery of blood circulation and tissue perfusion. This capability empowers medical professionals to immediately and interactively evaluate organ function and pathological conditions. The real-time feature proves particularly advantageous during interventional procedures, enabling physicians to accurately target and administer treatment at the moment. In comparison to imaging modalities like MRI and CT, CEUS boasts a generally more cost-effective profile, making it a viable option for healthcare systems aiming to optimize resources without compromising diagnostic precision.

The global CEUS market is projected to grow at a CAGR of 6.1% from an estimated USD 1.6 billion in 2023 to USD 2.1 billion by 2028, driven by the rising prevalence of chronic diseases and technological developments. Amidst the evolution in medical imaging technology, CEUS emerges as a safer, more accessible, and budget-friendly substitute for conventional imaging methods like CT scans and MRI. With its non-invasive characteristics and real-time imaging capacity, CEUS is bound to find increased adoption across various applications, encompassing liver and kidney imaging, vascular assessment, and the identification and characterization of tumors. Notably, the CEUS market is poised for rapid developments in contrast agents, which will improve image quality and diagnostic accuracy. Additionally, advancements in AI-powered image analysis are set to improve the interpretation and diagnosis of CEUS studies, granting healthcare practitioners the ability to make prompt and well-informed clinical judgments. Given the vast research and clinical evidence supporting the beneficial use of CEUS, regulatory authorities are likely to expand its approved applications, thereby driving greater acceptance and integration into routine medical practices. This growth in the CEUS market will ultimately translate into enhanced patient outcomes, more effective disease management, and a more patient-centric approach to medical imaging in the near future.

These are the latest findings of MarketsandMarkets (Northbrook, IL, USA), a market research firm.

Based on product, the equipment segment accounted for the highest share of the CEUS market in 2022 while the contrast agents segment is expected to register the highest CAGR over the forecast period. On the basis of application, the diagnostic applications segment accounted for the largest share of the CEUS market in 2022, while the therapeutic applications segment is expected to register the highest CAGR during the forecast period. Factors such as the introduction of novel software and the rising adoption of high-end instruments in end-user facilities will drive the growth of the therapeutic applications segment. Based on end-user, the hospital and surgical centers segment accounted for the largest share of the CEUS market in 2022, driven by the increasing geriatric population and rise in the number of hospitals. Geographically, the Asia Pacific CEUS market is anticipated to register the highest CAGR during the forecast period, driven by the expansion of manufacturing capabilities and the rise in the adoption of high-end equipment in the APAC region.

Related Links:
MarketsandMarkets 

New
Gold Member
X-Ray QA Meter
T3 AD Pro
CT Detector
PURE INSIGHT
New
Ultrasound Scanner
TBP-5533
NMUS & MSK Ultrasound
InVisus Pro

Print article
Radcal

Channels

Radiography

view channel
Image: The CT scanner prototype eliminates the need for physical compression of the breast (Photo courtesy of Quion Lowe and Lisa Dahm/U of A Cancer Center)

Novel Breast Cancer Screening Technology Could Offer Superior Alternative to Mammogram

Breast cancer represents 15.5% of new cancer cases and 7% of cancer-related deaths in the United States. Approximately 13.1% of women will be diagnosed with breast cancer during their lifetime.... Read more

Ultrasound

view channel
Image: Wearable ultrasound device offers continuous, long-term monitoring of muscle activity (Photo courtesy of Muyang Lin/UC San Diego)

Wearable Ultrasound Device Provides Long-Term, Wireless Muscle Monitoring

Electromyography (EMG) is the current clinical standard for monitoring muscle activity, utilizing metal electrodes placed on the skin to capture electrical signals from muscles. Despite its long-standing... Read more

Nuclear Medicine

view channel
Image: PET scans of a glioblastoma patient\'s brain, 72 hours after injection with the radiotracer (Photo courtesy of Dr Gabriela Kramer-Marek, The Institute of Cancer Research, London)

New Immuno-PET Imaging Technique Identifies Glioblastoma Patients Who Would Benefit from Immunotherapy

Glioblastoma is a type of brain tumor associated with a very poor prognosis, with average survival rates of 12 to 18 months and only 5% of patients surviving beyond five years. Research has shown that... Read more

General/Advanced Imaging

view channel
Image: Heavy smokers can ben Image (2):	efit from lung cancer screening using low-dose CT (Photo courtesy of 123RF)

Low-Dose CT Screening for Lung Cancer Can Benefit Heavy Smokers

Lung cancer is often diagnosed at a late stage, with only about one-fifth to one-sixth of patients surviving five years after diagnosis. A new report now suggests that low-dose computed tomography (CT)... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.